We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Sun2.7
Sunifiram (DM-235) Research
Mostly mechanism / observationalLimited safety
5 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Sunifiram (DM-235) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2002–2013.
Based on 5 studies
Confidence
Low
By outcome
Memory & cognition (rodent only, unproven in humans)
Mostly mechanism / observational5 studies
Focus & mental clarity (extrapolated, unproven for sunifiram)
These results indicate that DM235, a compound structurally related to piracetam, is a novel nootropic endowed with the capability to prevent cognitive deficits at very low doses. Indeed, its potency is about 1,000 times higher than that of the most active piracetam-like compounds.
Ghelardini C, Galeotti N, Gualtieri F, Romanelli MN, Bucherelli C, Baldi E, Bartolini A. · Naunyn-Schmiedeberg's Archives of Pharmacology (2002)
FOUNDATIONAL, RODENT-ONLY: the first pharmacological characterization of DM-235 (sunifiram), a piracetam-related nootropic, in mice and rats — no human subjects
Prevented scopolamine-, mecamylamine-, baclofen- and clonidine-induced amnesia in the mouse passive-avoidance test, and reversed scopolamine-impaired Morris water-maze learning in rats, implicating cholinergic and other systems
Active at extraordinarily low doses (0.001–0.1 mg/kg i.p. or 0.01–0.1 mg/kg p.o.), roughly 1,000-fold more potent than piracetam-like compounds, without impairing motor coordination or spontaneous activity
Taken together, sunifiram stimulates the glycine-binding site of NMDAR with concomitant PKCα activation through Src kinase. Enhancement of PKCα activity triggers to potentiate hippocampal LTP through CaMKII activation.
The spatial reference memory assessed by Y-maze and short-term memory assessed by novel object recognition task were significantly improved by sunifiram treatment in OBX mice ... sunifiram ameliorates OBX-induced deficits of memory-related behaviors and impaired LTP in the hippocampal CA1 region via stimulation of glycine-binding site of NMDAR.
Moriguchi S, Tanaka T, Tagashira H, Narahashi T, Fukunaga K. · Behavioural Brain Research (2013)
RODENT MODEL: in olfactory-bulbectomized mice (a model of cholinergic memory impairment), oral sunifiram (0.01–1.0 mg/kg) improved Y-maze spatial reference memory and novel-object-recognition short-term memory
Sunifiram restored hippocampal LTP and normalized CaMKIIα and GluR1 (AMPA-subunit) phosphorylation, plus PKCα and NR1 (NMDA-subunit) phosphorylation, to control levels
The behavioural and biochemical rescue was blocked by an NMDA glycine-site inhibitor (gavestinel), confirming the glycine-site / CaMKII / PKC mechanism in vivo
Some of the compounds display good antiamnesic and procognitive activity, with higher potency than piracetam, and with a potency similar to the parent compounds.
Martini E, Salvicchi A, Ghelardini C, Manetti D, Dei S, Guandalini L, Martelli C, Melchiorre M, Cellai C, Scapecchi S, Teodori E, Romanelli MN. · Bioorganic & Medicinal Chemistry (2009)
MEDICINAL CHEMISTRY + RODENT TEST: amides and sulfonamides structurally related to DM-235 (sunifiram) and MN19 (sapunifiram) were synthesized and tested for cognition-enhancing activity in the mouse passive-avoidance test
Confirms sunifiram and its analogues as potent antiamnesic / procognitive nootropics in mice, more potent than piracetam
Characterizes the structure-activity relationship of the sunifiram chemotype — relevant to identity and mechanism, but entirely preclinical
A series of analogs of DM235 and MN19, characterized by rings with different size, have been prepared and evaluated for their nootropic activity in the mouse passive-avoidance test.
Guandalini L, Martini E, Di Cesare Mannelli L, Dei S, Manetti D, Scapecchi S, Teodori E, Ghelardini C, Romanelli MN. · Bioorganic & Medicinal Chemistry Letters (2012)
MEDICINAL CHEMISTRY + RODENT TEST: ring-size analogues of DM-235 (sunifiram) and MN19 were prepared and evaluated for nootropic activity in the mouse passive-avoidance test
Defines the optimal ring geometry (6–7-membered ring) for the DM-235 chemotype's anti-amnesic activity, refining the structure-activity relationship
Reinforces that sunifiram's procognitive activity is a robust but ANIMAL-only finding across a chemical series